What is the early cure rate for cervical cancer?

The early cure rate of cervical cancer is usually 80%-90%, which is closely related to the pathological type, degree of differentiation and standardization of treatment.

Early-stage cervical cancer refers to the stage when the tumor is limited to the cervix and has not metastasized to lymph nodes or distant sites. At this time, the depth of cancer cell invasion usually does not exceed 5 mm. Patients with stage IA1 to IB1 in the International Federation of Gynecology and Obstetrics staging can achieve a higher survival rate through standardized treatment, which mainly uses surgical resection combined with lymph node dissection. Some patients require supplementary radiotherapy or concurrent chemoradiotherapy. Squamous cell carcinoma is more sensitive to radiotherapy than adenocarcinoma, and the prognosis of well-differentiated tumors is better than that of poorly differentiated types. No recurrence within 5 years after treatment can be regarded as clinical cure, but continuous follow-up is required to monitor the HPV infection status. The cure rate of patients detected by early screening is significantly higher than that of patients in the middle and late stages. Regular cervical cytology examination and HPV testing are the keys to improving the early diagnosis rate.

It is recommended that women of appropriate age undergo regular cervical cancer screening. HPV vaccination can prevent more than 70% of cervical cancer. Maintaining a single sexual partner and using condoms can help reduce the risk of HPV infection. After treatment, you need to avoid smoking, eat a balanced diet, and exercise moderately to enhance immunity. Reviews will be conducted every 3-6 months for two years after surgery, and will be changed to annual follow-up after five years. If abnormal vaginal bleeding or discharge occurs, seek medical attention promptly.